216 related articles for article (PubMed ID: 22357254)
21. Expression and mutational status of c-kit in thymic epithelial tumors.
Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Heinrich MC; Marino-Enriquez A; Presnell A; Donsky RS; Griffith DJ; McKinley A; Patterson J; Taguchi T; Liang CW; Fletcher JA
Mol Cancer Ther; 2012 Aug; 11(8):1770-80. PubMed ID: 22665524
[TBL] [Abstract][Full Text] [Related]
23. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Hsueh YS; Lin CL; Chiang NJ; Yen CC; Li CF; Shan YS; Ko CH; Shih NY; Wang LM; Chen TS; Chen LT
PLoS One; 2013; 8(6):e65762. PubMed ID: 23840364
[TBL] [Abstract][Full Text] [Related]
24. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
[TBL] [Abstract][Full Text] [Related]
26. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
Ströbel P; Hartmann M; Jakob A; Mikesch K; Brink I; Dirnhofer S; Marx A
N Engl J Med; 2004 Jun; 350(25):2625-6. PubMed ID: 15201427
[No Abstract] [Full Text] [Related]
27. [The diagnostic and predictive role of kit (CD117)].
Dirnhofer S; Zimpfer A; Went P
Ther Umsch; 2006 Apr; 63(4):273-8. PubMed ID: 16689459
[TBL] [Abstract][Full Text] [Related]
28. Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.
Dişel U; Oztuzcu S; Beşen AA; Karadeniz C; Köse F; Sümbül AT; Sezer A; Nursal GN; Abalı H; Ozyılkan O
Lung Cancer; 2011 Jan; 71(1):109-12. PubMed ID: 20970876
[TBL] [Abstract][Full Text] [Related]
29. A new KIT gene mutation in thymic cancer and a promising response to imatinib.
Lim SH; Lee JY; Sun JM; Kim KM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2013 Oct; 8(10):e91-2. PubMed ID: 24457249
[No Abstract] [Full Text] [Related]
30. Dedifferentiation in gastrointestinal stromal tumor to an anaplastic KIT-negative phenotype: a diagnostic pitfall: morphologic and molecular characterization of 8 cases occurring either de novo or after imatinib therapy.
Antonescu CR; Romeo S; Zhang L; Nafa K; Hornick JL; Nielsen GP; Mino-Kenudson M; Huang HY; Mosquera JM; Dei Tos PA; Fletcher CD
Am J Surg Pathol; 2013 Mar; 37(3):385-92. PubMed ID: 23348204
[TBL] [Abstract][Full Text] [Related]
31. Current and future management of GIST.
Blanke C
Clin Adv Hematol Oncol; 2006 Aug; 4(8):582-3. PubMed ID: 17099615
[No Abstract] [Full Text] [Related]
32. Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing.
Hagemann IS; Govindan R; Javidan-Nejad C; Pfeifer JD; Cottrell CE
J Thorac Oncol; 2014 Feb; 9(2):e12-6. PubMed ID: 24419427
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
34. Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit.
Dova L; Pentheroudakis G; Golfinopoulos V; Malamou-Mitsi V; Georgiou I; Vartholomatos G; Ntemou A; Fountzilas G; Pavlidis N
J Cancer Res Clin Oncol; 2008 Jun; 134(6):697-704. PubMed ID: 18064489
[TBL] [Abstract][Full Text] [Related]
35. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Hu S; Niu H; Minkin P; Orwick S; Shimada A; Inaba H; Dahl GV; Rubnitz J; Baker SD
Mol Cancer Ther; 2008 May; 7(5):1110-20. PubMed ID: 18483300
[TBL] [Abstract][Full Text] [Related]
36. Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study.
Rössle M; Hirschmann A; Diebold J
Eur J Cancer; 2011 Jun; 47(9):1305-11. PubMed ID: 21334201
[TBL] [Abstract][Full Text] [Related]
37. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
[TBL] [Abstract][Full Text] [Related]
38. [Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Wang ZY
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):641-5. PubMed ID: 20021856
[No Abstract] [Full Text] [Related]
39. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
40. Gastrointestinal stromal tumors.
Antonescu C
Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]